Belzer MPS® UW Machine Perfusion Solution
Proven solutions. Purposeful innovation. Uncompromising quality.
Belzer MPS® UW Machine Perfusion Solution
Proven solutions. Purposeful innovation. Uncompromising quality.
Committed Partner to the Transplant Community
Supply Agreements in Place with Multiple US Based Manufacturers
Minimum Inventory Levels of 60 days Assured to Protect from Shortages
Aseptically Manufactured in the US Using High Quality Bags to Prevent Product Failure in Critical Situations
Peelable Barcode Stickers – Saves Time and Avoids Errors
Advancing the Standard of Organ Preservation
Description
Belzer MPS® UW Machine Perfusion Solution is a sterile, isotonic non-pyrogenic solution with the following approximate calculations:
- Osmolarity of 300mOsm
- Sodium concentration of 100 mEq/L
- Potassium concentration of 25 mEq/L
- pH of 7.4 at 20° C
Supplied
1,000 mL in one-liter bags, shelf carton of 6
Storage
Belzer MPS® solution should be stored between 2°–25°C (36°–77°F). While 5°C is the ideal temperature for actual perfusion of Belzer MPS®, a range of 4°–8°C is acceptable.
Do not freeze or expose to excessive heat.
Usage
Belzer MPS® UW Machine Perfusion Solution is intended for the in vitro flushing and continuous machine perfusion preservation of explanted abdominal organs.
Belzer MPS® UW Machine Perfusion Solution is manufactured in the USA.
Product Literature
Wisconsin Alumni
Research Foundation
Follow WARF on LinkedIn.
Bridge to Life is honored to be a licensee of the Wisconsin Alumni Research Foundation (“WARF”). Bridge to Life is the exclusive licensee of WARF’s trademark, Belzer UW®.
The Wisconsin Alumni Research Foundation’s mission is to support scientific research at the University of Wisconsin-Madison. WARF accomplishes this by:
- Moving inventions arising from the university’s laboratories to the marketplace for the benefit of the university, the inventors and society
- Carefully managing an endowment that WARF has grown since its inception
Nearly all of the income from WARF’s transfer of technology and investment management is returned each year to the university to fund further scientific research.
Bridge to Life™ is designated as a WARF Startup Company. In addition to providing Bridge to Life™ various licenses, WARF also owns 5% of the total shares of Bridge to Life™, the first time that WARF has taken an equity position in a startup company.
Learn more about the vital role WARF plays in the development of science and its implementation into tomorrow’s technology - www.warf.org
